Jump to content
Sign in to follow this  

Aderans Research Enrolls 300Th Subject In Clinical Trial

Recommended Posts

Aderans Research reached a major milestone in its hair restoration studies recently when the company enrolled its 300th subject in Phase 2 of its clinical trial. With a goal of at least 350 subjects, Aderans is well on its way to expanding industry knowledge about cell-based engineering solutions for pattern hair loss.


“We will continue to evaluate various combinations of the Ji Gami™ cell family in clinical treatment regimens,” said Chief Executive Officer Ken Washenik, M.D., Ph.D.


“The results are very encouraging thus far, and we’re on course to finish Phase 2 next year,” added Vern Liebmann, Chief Operating Officer.


Launched in November 2008, Phase 2 is being conducted across the United States and is open to select individuals who suffer from androgenetic alopecia. Aderans continues to recruit subjects; visit http://www.aderansre...nicupdates.html for current locations.


In another landmark, Aderans recently patented (U.S. # 7,985,537) and trademarked its proprietary laboratory test, Aderans HPA™, developed to discern and assess cell formulations in terms of their hair-forming ability. “This unique test can effectively detect cells that produce hair follicles,” said Kurt Stenn, MD, Vice President and Chief Scientific Officer. “It is a standard in the industry.”


Full hair loss article

Share this post

Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

  • Create New...